Immune System News and Research

RSS

PLX-PAD therapy improves quality of life in CLI patients

Pluristem Therapeutics Inc. today reported that data from clinical trials show the Company's placenta-derived cell therapy, PLX-PAD, is safe and improves quality of life as well as other efficacy measurements in patients with Critical Limb Ischemia (CLI), the end-stage of Peripheral Artery Disease (PAD).

15 Sep 2010

Pregnant women should get immunized against flu

There will be only one flu shot needed this year and pregnant women should make sure they're at the front of the line to get it.

15 Sep 2010

USF receives grant for studying ways to protect fetal brain from maternal infection

University of South Florida (USF) neuroscientists have been awarded a $400,000 federal grant to study ways of protecting the developing fetal brain from the damaging effects of maternal infections, a suspected cause for certain types of autism.

15 Sep 2010

Atox Bio doses first subject in AB103 Phase 1 study for severe bacterial infections and sepsis

Atox Bio Inc. today announced that it successfully completed the dosing of the first subject in its phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.

15 Sep 2010

Arizona State University receives grant to protect warfighters from infectious diseases

Scientists at the Biodesign Institute at Arizona State University have received a 2-year, $5.3 million grant from the Defense Advanced Research Projects Agency (DARPA) to protect warfighters in the event of exposure to infectious diseases during deployment.

15 Sep 2010

Cetaphil launches Restoraderm for management of eczema and atopic dermatitis skin

The Cetaphil® brand, the #1 dermatologist-recommended brand of cleansers and moisturizers announced the launch of Cetaphil® Restoraderm® products, formulated specifically for the needs of eczema and atopic dermatitis skin. Cetaphil® Restoraderm® Skin Restoring Body Wash and Skin Restoring Moisturizer soothes itching associated with skin affected by eczema and atopic dermatitis.

14 Sep 2010

VBL Therapeutics' VB-201 candidate delays onset of EAE, shows potential for MS, CNS treatment

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the publication of preclinical data in the Journal of Neuroimmunology finding that its lead development candidate VB-201 significantly delayed the onset and severity of experimental autoimmune encephalomyelitis (EAE) in mice, the commonly used Multiple sclerosis.

14 Sep 2010

Researchers demonstrate shape memory alloys in medical implants

A European team has demonstrated that modern technological materials used in a wide range of medical devices and implants are entirely biocompatible and should not health problems as has previously been suggested.

14 Sep 2010

Gladstone Institute elects for 2010 recipient of Avant-Garde Award for HIV/AIDS Research

The National Institute on Drug Abuse, part of the National Institutes of Health, announced today that Dr. Eric M. Verdin of the J. David Gladstone Institutes in San Francisco, Calif., has been selected as the 2010 recipient of the NIDA Avant-Garde Award for HIV/AIDS Research for his proposal to study the mechanisms of latent HIV infection.

14 Sep 2010

Notch1 protein impacts childhood leukemia progression: Study

A protein crucial for the immune response appears to be a key player in the progression of a devastating form of childhood leukemia called T-cell acute lymphoblastic leukemia (T-ALL). Suppressing the activity of the protein kills the leukemic cells, the study shows, opening a potential avenue to new drugs that could prevent progression of the disease.

14 Sep 2010

Excelimmune presents positive results for HRPA therapy against MRSA infections

Excelimmune, Inc. announced positive results from preclinical studies evaluating the efficacy of its human recombinant polyclonal antibody (HRPA) therapy against infections caused by methicillin-resistant Staphylococcus aureus (MRSA).

14 Sep 2010

Sanofi Pasteur files Fluzone Intradermal influenza virus vaccine sBLA with FDA

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has filed a Supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) for Fluzone® Intradermal (Influenza Virus Vaccine). The file has been accepted by the FDA and an action date is anticipated in the first half of 2011.

From BD (Becton, Dickinson and Company) 14 Sep 2010

New book relates mercury in vaccines to autism

The U.S. government revealed last week that they will compensate a family millions of dollars for their daughter's injury related to her infant vaccines that contained mercury and the subsequent development of autism. Yet, the CDC continues to tell the public that there is no connection between vaccines and autism and that the mercury has been removed, although the flu shot recommended for all pregnant women, infants, and children continues to be preserved with mercury.

13 Sep 2010

Vical's TransVax CMV vaccine achieves key endpoints in Phase 2 trial in immunocompromised HCT recipients

Vical Incorporated announced today the achievement of key efficacy, immunogenicity and safety results in a Phase 2 trial, establishing its TransVax™ cytomegalovirus (CMV) vaccine as the first to provide evidence of protection in immunocompromised hematopoietic cell transplant (HCT) recipients, and defining a potential pathway for further development.

13 Sep 2010

Athersys signs agreement with RTI Biologics for MAPC technology access

RTI Biologics Inc., a leading provider of orthopedic and other biologic implants, and Athersys Inc. a leader in regenerative medicine and cell therapy research and development, announced today an agreement under which Athersys will provide RTI access to its Multipotent Adult Progenitor Cell (MAPC) technologies.

13 Sep 2010

Leukemia survivor to meet donor of bone marrow transplant

Ann Marie Del Fiacco, a 38-year-old Berwyn mother of two, owes her life to a stranger who volunteered to be a donor for her life-saving bone marrow transplant.

13 Sep 2010

Octapharma sponsors symposium on inhibitors in Haemophilia A

In a showing of its continued commitment to eradicating today's major complication in the treatment of haemophilia with FVIII concentrates − i.e. anti-FVIII neutralising antibodies − Octapharma AG recently sponsored a symposium, "Inhibitors in Haemophilia A: Prevention, Current Management and Personalised Therapy Perspectives", on July 13, 2010 at the World Federation of Haemophilia's (WFH's) yearly congress.

13 Sep 2010

Inovio Pharmaceuticals achieves promising results in VGX-3100 Phase I study

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has achieved best-in-class immune responses in its Phase I dose escalation study of VGX-3100, its DNA vaccine to treat pre-cancerous cervical dysplasias and cervical cancers caused by human papillomavirus (HPV) types 16 and 18.

13 Sep 2010

Rib-X Pharmaceuticals presents preclinical data of radezolid drug at ICAAC Conference

Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced the presentation of positive preclinical data for radezolid at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) conference.

13 Sep 2010

PCRI to host educational event on prostate cancer therapy

Dean Ornish MD, recognized for establishing the impact of diet on prostate cancer (and heart disease), along with over a dozen internationally recognized prostate cancer experts will meet with over 800 prostate cancer survivors and their significant others at the Los Angeles Marriott near LAX on September 11th and 12th to discuss the latest thinking on prostate cancer treatment.

13 Sep 2010

Immune System News and Research

PLX-PAD therapy improves quality of life in CLI patients

Pregnant women should get immunized against flu

USF receives grant for studying ways to protect fetal brain from maternal infection

Atox Bio doses first subject in AB103 Phase 1 study for severe bacterial infections and sepsis

Arizona State University receives grant to protect warfighters from infectious diseases

Cetaphil launches Restoraderm for management of eczema and atopic dermatitis skin

VBL Therapeutics' VB-201 candidate delays onset of EAE, shows potential for MS, CNS treatment

Researchers demonstrate shape memory alloys in medical implants

Gladstone Institute elects for 2010 recipient of Avant-Garde Award for HIV/AIDS Research

Notch1 protein impacts childhood leukemia progression: Study

Excelimmune presents positive results for HRPA therapy against MRSA infections

Sanofi Pasteur files Fluzone Intradermal influenza virus vaccine sBLA with FDA

New book relates mercury in vaccines to autism

Vical's TransVax CMV vaccine achieves key endpoints in Phase 2 trial in immunocompromised HCT recipients

Athersys signs agreement with RTI Biologics for MAPC technology access

Leukemia survivor to meet donor of bone marrow transplant

Octapharma sponsors symposium on inhibitors in Haemophilia A

Inovio Pharmaceuticals achieves promising results in VGX-3100 Phase I study

Rib-X Pharmaceuticals presents preclinical data of radezolid drug at ICAAC Conference

PCRI to host educational event on prostate cancer therapy

Immunology eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News